دورية أكاديمية

Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study.

التفاصيل البيبلوغرافية
العنوان: Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study.
المؤلفون: Dreicer R; Departments of Hematology/Oncology and Urology, The Cleveland Clinic Foundation, Cleveland, OH, USA. dreicer@ccf.org, Manola J, Roth BJ, Cohen MB, Hatfield AK, Wilding G
المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2000 Mar; Vol. 18 (5), pp. 1058-61.
نوع المنشور: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
اللغة: English
بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print Cited Medium: Print ISSN: 0732-183X (Print) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2003- : Alexandria, VA : American Society of Clinical Oncology
Original Publication: New York, N.Y. : Grune & Stratton, c1983-
مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Transitional Cell/*drug therapy , Cisplatin/*therapeutic use , Paclitaxel/*therapeutic use , Urologic Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Treatment Outcome ; Urothelium
مستخلص: Purpose: Cisplatin and paclitaxel are active agents in advanced urothelial cancer. A phase II trial of this combination was performed to determine the activity and toxicity of these agents in a multi-institutional setting.
Patients and Methods: Fifty-two patients with advanced urothelial carcinoma were treated on one day with paclitaxel 175 mg/m(2) over 3 hours followed by cisplatin 75 mg/m(2), both intravenously, every 21 days. Cycles were repeated every 21 days until progression or a maximum of six cycles.
Results: Twenty-six patients obtained an objective response, for an overall response rate of 50% (95% confidence interval, 36% to 64%). Four patients achieved complete clinical responses. The median overall survival time for the group was 10.6 months. Toxicity was moderate, with granulocytopenia and neurotoxicity being the most common side effects noted.
Conclusion: The combination of cisplatin and paclitaxel is active in advanced urothelial cancer. Responses in visceral, nodal, and soft tissues sites were observed. Granulocytopenia without fever and grade 2/3 neurotoxicity were common. The confidence interval of the overall response rate in this study overlaps most of the other reported regimens. The optimal therapy for advanced urothelial cancer remains undefined.
معلومات مُعتمدة: CA21076 United States CA NCI NIH HHS; CA23318 United States CA NCI NIH HHS; CA49883 United States CA NCI NIH HHS; etc.
المشرفين على المادة: P88XT4IS4D (Paclitaxel)
Q20Q21Q62J (Cisplatin)
تواريخ الأحداث: Date Created: 20000301 Date Completed: 20000324 Latest Revision: 20170210
رمز التحديث: 20221213
DOI: 10.1200/JCO.2000.18.5.1058
PMID: 10694557
قاعدة البيانات: MEDLINE
الوصف
تدمد:0732-183X
DOI:10.1200/JCO.2000.18.5.1058